LABA/LAMA双联支气管扩张剂在硅沉着病合并COPD患者中的临床疗效  

Clinical Efficacy of LABA/LAMA Duplex Bronchodilators in Patients with Silicosis Complicated with COPD

作　　者：王晶 王琳 朱辉 WANG Jing;WANG Lin;ZHU Hui(Department of Respiratory and Critical Care Medicine,the Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221006,China;不详)

机构地区：[1]徐州医科大学第二附属医院呼吸重症医学科,江苏徐州221006

出　　处：《中国医学创新》2024年第16期95-99,共5页Medical Innovation of China

基　　金：润物有声-白求恩·中青年医生慢阻肺科研发展基金之支扩剂合理应用科研项目(BJRW2020021J)。

摘　　要：目的:探讨长效β_(2)受体激动药(LABA)/长效抗胆碱能药物(LAMA)双联支气管扩张剂在治疗硅沉着病合并慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者中的临床效果。方法:选取2019年2月—2020年8月徐州医科大学第二附属医院收治的100例硅沉着病合并COPD患者,按照随机数字表法分为观察组和对照组,每组50例。观察组吸入LABA/LAMA双联支气管扩张剂(茚达特罗格隆溴铵),对照组吸入布地奈德福莫特罗。比较两组在治疗前,以及治疗1、3、6、12个月后的肺功能第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)。比较两组治疗前、治疗12个月后测定的改良呼吸困难指数(mMRC)、BODE指数。比较两组治疗12个月期间急性加重风险和肺炎发生风险。结果:治疗3、6、12个月后,两组FEV_(1)、FVC均较治疗前明显升高,且观察组均高于对照组(P<0.05)。治疗12个月后,两组mMRC评分和BODE指数较治疗前略降低,差异均无统计学意义(P>0.05)。观察组急性加重风险和肺炎发生风险显著低于对照组,差异有统计学意义(P<0.05)。结论:LABA/LAMA双联支气管扩张剂在治疗硅沉着病合并COPD患者的效果显著,且安全性更高。Objective:To investigate the clinical efficacy of long-actingβ_(2)agonist(LABA)/long-acting muscarinic antagonists(LAMA)duplex bronchodilators in the treatment of silicosis complicated with chronic obstructive pulmonary disease(COPD).Method:A total of 100 patients with silicosis complicated with COPD admitted to the Second Affiliated Hospital of Xuzhou Medical University from February 2019 to August 2020 were selected,and divided into observation group and control group according to random number table method,with 50 cases in each group.The observation group received LABA/LAMA duplex bronchodilators(Indacaterol Maleate and Glycopyrronium Bromide),the control group received Budesonide and Formoterol.The pulmonary function forced expiratory volume at the first second(FEV_(1))and forced vital capacity(FVC)of the two groups were compared before treatment at 1,3,6 and 12 months.The modified medical research council(mMRC)and BODE index were compared between the two groups before treatment and 12 months after treatment.The risk of acute exacerbation and pneumonia were compared between the two groups during 12 months of treatment.Result:After treatment for 3,6 and 12 months,FEV_(1) and FVC in two groups were significantly higher than those before treatment,and those in the observation group were higher than those in control group(P<0.05).After 12 months of treatment,mMRC score and BODE index in both groups were slightly decreased than those before treatment,the differences were not statistically significant(P>0.05).The risk of acute exacerbation and pneumonia in observation group were significantly lower than those in control group,the difference was statistically significant(P<0.05).Conclusion:LABA/LAMA duplex bronchodilators has a significant effect and higher safety in the treatment of patients with silicosis complicated with COPD.

关 键 词：长效β_(2)受体激动药 长效抗胆碱能药物 慢性阻塞性肺疾病 硅沉着病 

分 类 号：R563[医药卫生—呼吸系统]